Yongjie Zhuo

Yongjie Zhuo

Auto-generated profile, based on publicly available information

Yongjie Zhuo

Department of Nephrology, Blood Purification Research Center, The First Affiliated Hospital Fujian Medical University Fuzhou China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Journal of Diabetes Research
Verified
Journal Article
Open access
YZYongjie Zhuo
Yongjie Zhuo
MWMengjie Weng
Mengjie Weng
JLJiaqun Lin
Jiaqun Lin
XWXiaoting Wu
Xiaoting Wu
KNKun Nie
Kun Nie
JWJianxin Wan
Jianxin Wan
Purpose: Chronic inflammation plays a key role in diabetic nephropathy (DN), yet the impact of tertiary lymphoid structures (TLSs) on disease progression remains poorly understood. This study explored the relationship between TLS maturity and renal outcomes in patients with DN. Methods: This study included 117 biopsy‐confirmed DN patients from the First Affiliated Hospital of Fujian Medical University. Patients were grouped based on TLS maturity, as determined by immunohistochemical staining. Clinical, laboratory, and pathological data were gathered, and Cox regression models were applied to assess renal outcome risk factors. Kaplan–Meier curves were constructed to compare renal survival among groups. A web‐based model integrating TLS maturity, urinary albumin‐to‐creatinine ratio (UACR), and renal pathology classification was developed. Results: Mature TLSs were associated with worse renal prognosis, with greater disease progression in the TLS+ group (75.4% vs. 53.3%, p = 0.006). Multivariate Cox regression analysis identified TLS maturity (HR = 1.819, 95% CI: 1.144–2.893, p = 0.011), DN glomerular classification (HR = 1.511, 95% CI: 1.057–2.160, p = 0.024), and UACR (HR = 1.121, 95% CI: 1.038–1.210, p = 0.004) as independent risk factors. The dynamic nomogram demonstrated strong predictive performance. Conclusions: TLS maturity independently predicts renal function decline in DN and may support personalized risk assessment through a web‐based model.

11 October 2026 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
KNKun Nie
Kun Nie
XGXiaowei Gao
Xiaowei Gao
MLMinggang Liu
Minggang Liu
DYDanyu You
Danyu You
MWMengjie Weng
Mengjie Weng
LYLiyan Yang
Liyan Yang
Minimal change disease (MCD) frequently relapses, and infection is one of the most common clinical triggers. Arachidonic acid (AA), an inflammatory lipid mediator released during tissue injury and infection, has been implicated in podocyte injury, but its contribution to metabolic dysfunction in MCD remains unclear. Here, we investigated whether AA aggravates PAN‐induced podocyte injury and examined the involvement of pyruvate kinase M2 (PKM2)‐associated metabolic dysfunction. In a puromycin aminonucleoside (PAN)‐induced rat model, AA exposure increased serum AA levels, aggravated proteinuria, reduced nephrin expression, promoted foot‐process effacement and exacerbated mitochondrial dysfunction. AA was also associated with reduced PKM1 and PKM2 abundance, increased PKM2 (Tyr105) phosphorylation, decreased pyruvate kinase activity and lower pyruvate, lactate and ATP levels. In cultured human podocytes, AA intensified PAN‐induced cytoskeletal disruption, mitochondrial dysfunction, oxidative stress and apoptosis. Pharmacological activation of PKM2 with TEPP‐46 partially restored PK‐associated metabolic activity, improved mitochondrial readouts and attenuated podocyte injury in vitro. These findings suggest that AA exacerbates PAN‐induced podocyte injury in association with PKM2‐associated metabolic dysfunction and mitochondrial stress.